Parkinson's Disease
Conditions
Brief summary
Time to confirmed worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score over the treatment period.
Detailed description
Incidence of AEs and SAEs during the treatment period, Time to confirmed worsening in MDS-UPDRS Part II score over the treatment period, Change in MDS-UPDRS Parts II and III combined score, Time to confirmed worsening in Schwab and England Activities of Daily Living Scale (SEADL) over the treatment period, Change in MDS-UPDRS Parts I, II, and III combined score
Interventions
Sponsors
Biogen Idec Research Limited
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to confirmed worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score over the treatment period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of AEs and SAEs during the treatment period, Time to confirmed worsening in MDS-UPDRS Part II score over the treatment period, Change in MDS-UPDRS Parts II and III combined score, Time to confirmed worsening in Schwab and England Activities of Daily Living Scale (SEADL) over the treatment period, Change in MDS-UPDRS Parts I, II, and III combined score | — |
Countries
Austria, France, Germany, Italy, Netherlands, Poland, Spain
Outcome results
None listed